Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsFRA:01P +0.49%95 PB Ratio is 39.31 as of Jul. 25, 2026, which is 436% above its 10-year median of 7.33. GuruFocus rates FRA:01P with a GF Score™ of 95/100 and a GF Value™ of €463.14 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Medpace Holdings ranks worse than 97.95% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-25), Medpace Holdings's share price is €530.40. Medpace Holdings's Book Value per Share for the quarter that ended in Jun. 2026 was €13.49. Hence, Medpace Holdings's PB Ratio of today is 39.31.
The historical rank and industry rank for Medpace Holdings's PB Ratio or its related term are showing as below:
FRA:01P'
s PB Ratio Range Over the Past 10 Years
Min: 1.51 Med: 7.33 Max: 81.26
Current: 38.68
During the past 13 years, Medpace Holdings's highest PB Ratio was 81.26. The lowest was 1.51. And the median was 7.33.
FRA:01P's PB Ratio is ranked worse than 97.95% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.01
vs FRA:01P: 38.68
During the past 12 months, Medpace Holdings's average Book Value Per Share Growth Rate was 153.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -3.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 4.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Medpace Holdings was 17.00% per year. The lowest was -14.90% per year. And the median was 10.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Medpace Holdings PB Ratio Related Terms
Medpace Holdings PB Ratio Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Medpace Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Medpace Holdings (FRA:01P) has a PB Ratio of 39.31 as of Jul. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medpace Holdings and its competitors. This is 436% above median its historical median of 7.33. Over the past decade, Medpace Holdings' PB Ratio has ranged from 1.51 to 81.26. According to the industry distribution chart, Medpace Holdings ranks #191 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 97.9%.
Is Medpace Holdings' PB Ratio too high?
Medpace Holdings' current PB Ratio of 39.31 is 436% above median its 10-year median of 7.33. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 81.26. The Medical Diagnostics & Research industry median PB Ratio is 2.01. Medpace Holdings' value of 39.31 is 1855.7% above this industry median. Based on the distribution chart, Medpace Holdings ranks #191 out of 195 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Medpace Holdings has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' PB Ratio compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #191 out of 195 companies for PB Ratio. This places Medpace Holdings in the lower half of its industry. The industry median PB Ratio is 2.01. Medpace Holdings' value of 39.31 is 1855.7% above this benchmark. Historically, Medpace Holdings' own PB Ratio has ranged from 1.51 to 81.26 over the past decade. While the company's 10-year median is 7.33 vs. the industry median of 2.01, Medpace Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.01, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current PB Ratio of 39.31 is 1855.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current PB Ratio is 39.31, which is 436% above median its own 10-year median of 7.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (FRA:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €463.14, compared to a current price of €530.40 — trading 14.5% above its estimated fair value. The current PB Ratio is 39.31, which is 436% above median its 10-year median of 7.33 and 1855.7% above the Medical Diagnostics & Research industry median of 2.01. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Medpace Holdings (FRA:01P), the current PB Ratio is 39.31 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (FRA:01P) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of €530.40 is trading 14.5% above its estimated GF Value™ of €463.14.
GuruFocus considers Medpace Holdings to be Modestly Overvalued.
Key valuation signals for FRA:01P:
PB Ratio: 39.31 (436% above median its 10-year median of 7.33)
GF Value™: €463.14 vs. price of €530.40 (14.5% above fair value)
Industry Position: 1855.7% above the Medical Diagnostics & Research median (#191 of 195)
No single metric tells the full story. See the FRA:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for FRA:01P
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:01P has been successfully added to your 
